Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?

Clinical Cancer Research

Volumn 21, Issue 9, 2015, Pages 2001-2008

  Paiva, Bruno ^a   Puig, Noemi ^b   García Sanz, Ramón ^b   San Miguel, Jesús F ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGONUCLEOTIDE;

ALLELE; FLOW CYTOMETRY; GENE REARRANGEMENT; HEMODILUTION; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOPHENOTYPING; INTERMETHOD COMPARISON; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; TREATMENT RESPONSE; NEOPLASM, RESIDUAL;

HUMANS; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL;

EID: 84941950952     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2841     Document Type: Review

References (75)

1. Mateos MV, San Miguel JF. How should we treat newly diagnosed multiple myeloma patients? Hematology Am Soc Hematol Educ Program 2013; 2013:488-95.
2. McCarthy PL, Hahn T. Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients. Hematology Am Soc Hematol Educ Program 2013;2013:496-503.
3. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28:1122-8.
4. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.
5. Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol 2013;31: 4529-35.
6. de Larrea CF, Cibeira MT, Elena M, Arostegui JI, Rosinol L, Rovira M, et al. Abnormal serum free light chain ratio in patients with multiplemyeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. Blood 2009;114:4954-6.
7. Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011;29:1627-33.
8. San-Miguel JF, Paiva B, Gutiérrez NC. New tools for diagnosis and monitoring of multiple myeloma. Am Soc Clin Oncol Educ Book 2013.
9. Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood 2013; 121:1819-23.
10. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 2011;118:5989-95.
11. Almeida J, Orfao A, Ocqueteau M, Mateo G, Corral M, Caballero MD, et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol 1999;107:121-31.
12. Garcia-Sanz R, Orfao A, Gonzalez M, Tabernero MD, Blade J, Moro MJ, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999;93:1032-7.
13. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004;121: 482-8.
14. Rawstron AC, Barrans SL, Blythe D, English A, Richards SJ, Fenton JA, et al. In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression. Br J Haematol 2001;113:794-802.
15. Dahl IM, Rasmussen T, Kauric G, Husebekk A. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol 2002;116:273-7.
16. Davies FE, Forsyth PD, Rawstron AC, Owen RG, Pratt G, Evans PA, et al. The impact of attaining a minimal disease state after high-dosemelphalan and autologous transplantation for multiple myeloma. Br J Haematol 2001;112:814-9.
17. Mateo MG, San MI, Orfao de MA. Immunophenotyping of plasma cells in multiple myeloma. Methods Mol Med 2005;113:5-24.
18. Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005;106:2276-9.
19. Perez-Andres M, Almeida J, Martin-Ayuso M, Moro MJ, Martin-Nunez G, Galende J, et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 2005;19:449-55.
20. Rawstron AC, Davies FE, Das Gupta R, Ashcroft AJ, Patmore R, Drayson MT, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100:3095-100.
21. Robillard N, Pellat-Deceunynck C, Bataille R. Phenotypic characterization of the human myeloma cell growth fraction. Blood 2005;105:4845-8.
22. San Miguel JF, Almeida J, Mateo G, Blade J, Lopez-Berges C, Caballero D, et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002;99:1853-6.
23. San Miguel JF, Gutierrez NC, Mateo G, Orfao A. Conventional diagnostics in multiple myeloma. Eur J Cancer 2006;42:1510-9.
24. Moreau P, Robillard N, Jego G, Pellat C, Le Gouill S, Thoumi S, et al. Lack of CD27 in myeloma delineates different presentation and outcome. Br J Haematol 2006;132:168-70.
25. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008;93:431-8.
26. Paiva B, Almeida J, Perez-Andres M, Mateo G, Lopez A, Rasillo A, et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom 2010; 78:239-52.
27. van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012;26:1908-75.
28. Davies FE, Rawstron AC, Owen RG, Morgan GJ. Minimal residual disease monitoring in multiple myeloma. Best Pract Res Clin Haematol 2002;15: 197-222.
29. Martinelli G, Terragna C, Lemoli RM, Cavo M, Benni M, Motta MR, et al. Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells. Haematologica 1999;84:397-404.
30. Owen RG, Goulden NJ, Oakhill A, Shiach C, Evans PA, Potter MN, et al. Comparison of fluorescent consensus IgH PCR and allele-specific oligonucleotide probing in the detection of minimal residual disease in childhood ALL. Br J Haematol 1997;97:457-9.
31. Boyd SD, Gaeta BA, Jackson KJ, Fire AZ, Marshall EL, Merker JD, et al. Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangements. J Immunol 2010;184:6986-92.
32. Freeman JD, Warren RL, Webb JR, Nelson BH, Holt RA. Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. Genome Res 2009;19:1817-24.
33. Robins H, Desmarais C, Matthis J, Livingston R, Andriesen J, Reijonen H, et al. Ultra-sensitive detection of rare T cell clones. J Immunol Methods 2012;375:14-9.
34. Logan AC, Zhang B, Narasimhan B, Carlton V, Zheng J, Moorhead M, et al. Minimal residual disease quantification using consensus primers and highthroughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia 2013;27:1659-65.
35. Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E, et al. Deep-sequencing approach forminimal residual disease detection in acute lymphoblastic leukemia. Blood 2012;120:5173-80.
36. Huff CA, Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol 2008;26:2895-900.
37. Thiago LS, Perez-Andres M, Balanzategui A, Sarasquete ME, Paiva B, Jara-Acevedo M, et al. Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 2014;99:155-62.
38. Ferrero S, Drandi D, Mantoan B, Ghione P, Omede P, Ladetto M. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. Hematol Oncol 2011;29:167-76.
39. Sarasquete ME, Garcia-Sanz R, Gonzalez D, Martinez J, Mateo G, Martinez P, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005;90: 1365-72.
40. Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003;102:1927-9.
41. Korthals M, Sehnke N, Kronenwett R, Bruns I, Mau J, Zohren F, et al. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter. Biol Blood Marrow Transplant 2012;18:423-31 e3.
42. Langerak AW, Groenen PJ, Bruggemann M, Beldjord K, Bellan C, Bonello L, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 2012;26:2159-71.
43. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007;2:604-11.
44. Biran N, Ely S, Chari A. Controversies in the assessment ofminimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques. Curr Hematol Malig Rep 2014;9:368-78.
45. Cooke F, Bakkus M, Thielemans K, Pico JL, Apperley JF, Samson D. Use of quantitative ASO-PCR to predict relapse in multiple myeloma. Br J Haematol 1999;105:317-9.
46. Garcia-Sanz R, Lopez-Perez R, Langerak AW, Gonzalez D, Chillon MC, Balanzategui A, et al. Heteroduplex PCR analysis of rearranged immunoglobulin genes for clonality assessment in multiple myeloma. Haematologica 1999;84:328-35.
47. Kosmas C, Stamatopoulos K, Stavroyianni N, Zoi K, Belessi C, Viniou N, et al. Origin and diversification of the clonogenic cell in multiple myeloma: lessons from the immunoglobulin repertoire. Leukemia 2000;14: 1718-26.
48. Sahota SS, Leo R, Hamblin TJ, Stevenson FK. Myeloma VL and VH gene sequences reveal a complementary imprint of antigen selection in tumor cells. Blood 1997;89:219-26.
49. Puig N, Sarasquete ME, Balanzategui A, Martinez J, Paiva B, Garcia H, et al. Critical evaluation of ASORQ-PCR forminimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia 2014;28:391-7.
50. Puig N, Sarasquete ME, Alcoceba M, Balanzategui A, Chillon MC, Sebastian E, et al. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma. Ann Hematol 2013;92:97-100.
51. Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R, et al. Prognostic value of deep sequencing method forminimal residual disease detection in multiple myeloma. Blood 2014;123:3073-9.
52. Boyd SD, Marshall EL, Merker JD, Maniar JM, Zhang LN, Sahaf B, et al. Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci Transl Med 2009;1:12ra23.
53. Martinez-Lopez J, Fulciniti M, Barrio S, Carlton V, Moorhead M, Lahuerta JJ, et al. Deep sequencing reveals oligoclonality at the immunoglobulin locus in multiple myeloma patients [abstract]. In: Proceedings of the 55th ASH Annual Meeting and Exposition; 2013 Dec 7-10; New Orleans, LA and Washington, DC: American Society of Hematology. Abstract nr 401.
54. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257-317.
55. Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112:4017-23.
56. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013;31:2540-7.
57. Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012;119:687-91.
58. Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol 2014;32:2712-7.
59. Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Boccadoro M, et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995;85:1596-602.
60. Bjorkstrand B, Ljungman P, Bird JM, Samson D, Gahrton G. Double highdose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant 1995;15:367-71.
61. Swedin A, Lenhoff S, Olofsson T, Thuresson B, Westin J. Clinical utility of immunoglobulin heavy chain gene rearrangement identification for tumour cell detection in multiple myeloma. Br J Haematol 1998;103:1145-51.
62. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A, et al. Molecular and clinical remissions inmultiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999;17:208-15.
63. Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli R, et al. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica 2000;85:930-4.
64. Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli RM, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000;18: 2273-81.
65. Cavo M, Terragna C, Martinelli G, Ronconi S, Zamagni E, Tosi P, et al. Molecular monitoring ofminimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 2000;96:355-7.
66. Ladetto M, Donovan JW, Harig S, Trojan A, Poor C, Schlossnan R, et al. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant 2000;6:241-53.
67. Bakkus MH, Bouko Y, Samson D, Apperley JF, Thielemans K, Van Camp B, et al. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol 2004;126:665-74.
68. Martinez-Sanchez P, Montejano L, Sarasquete ME, Garcia-Sanz R, Fernandez-Redondo E, Ayala R, et al. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response. Br J Haematol 2008;142:766-74.
69. Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010;28:2077-84.
70. Putkonen M, Kairisto V, Juvonen V, Pelliniemi TT, Rauhala A, Itala-Remes M, et al. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. Eur J Haematol 2010;85:416-23.
71. Ferrero S, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M, et al. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. Leukemia 2015;29:689-95.
72. Lipinski E, Cremer FW, Ho AD, Goldschmidt H, Moos M. Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2001;28: 957-62.
73. Lioznov M, Badbaran A, Fehse B, Bacher U, Zander AR, Kroger NM. Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques. Bone Marrow Transplant 2008;41:913-6.
74. Ladetto M, Bruggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 2014;28: 1299-307.
75. Galimberti S, Benedetti E, Morabito F, Papineschi F, Callea V, Fazzi R, et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res 2005;29: 961-6.